This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
M Arendt , PB Mortensen , R Rosenberg , CB Pedersen , BL Waltoft (2008). Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Archives of General Psychiatry 65, 269–274.
S Arndt , G Tyrrell , M Flaum , NC Andreasen (1992). Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychological Medicine 22, 379–388.
L Arseneault , M Cannon , R Poulton , R Murray , (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212–1213.
L Arseneault , M Cannon , J Witton , RM Murray (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110–117.
I Baeza , M Graell , D Moreno , J Castro-Fornieles , (2009). Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research 113, 129–137.
TR Barnes , SH Mutsatsa , SB Hutton , HC Watt , (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 188, 237–242.
M Beiser , D Erickson , JA Fleming , WG Iacono (1993). Establishing the onset of psychotic illness. American Journal of Psychiatry 150, 1349–1354.
S Bhattacharyya , P Fusar-Poli , S Borgwardt , (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66, 442–451.
MG Bossong , BN van Berckel , R Boellaard , (2009). 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759–766.
MF Brunette , KT Mueser , H Xie , RE Drake (1997). Relationships between symptoms of schizophrenia and substance abuse. Journal of Nervous and Mental Disease 185, 13–20.
B Bühler , M Hambrecht , W Loffler , W an der Heiden , (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse. A retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 54, 243–251.
A Caspi , TE Moffitt , M Cannon , J McClay , (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biological Psychiatry 57, 1117–1127.
MT Compton , NE Whicker , KM Hochman (2007). Alcohol and cannabis use in urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. Journal of Clinical Psychiatry 68, 1939–1945.
A Cougnard , M Marcelis , I Myin-Germeys , R De Graaf , (2007). Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychological Medicine 37, 513–527.
DC D'Souza , WM Abi-Saab , S Madonick , K Forselius-Bielen , (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594–608.
DC D'Souza , RA Sewell , M Ranganathan (2009). Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience 259, 413–431.
LE DeLisi (1992). The significance of age at onset for schizophrenia. Schizophrenia Bulletin 18, 209–215.
H Erhenreich , T Rinn , HJ Kunert , MR Moeller , (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142, 295–301.
AI Green , DL Noordsy , MF Brunette , C O'Keefe (2008). Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment 34, 61–71.
AI Green , MF Tohen , RM Hamer , SM Strakowski , (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 66, 125–135.
C Henquet , M Di Forti , P Morrison , (2008). Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111–1121.
C Henquet , L Krabbendam , J Spauwen , C Kaplan , (2005 a). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11.
C Henquet , R Murray , D Linszen , J van Os (2005 b). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608–612.
L Hides , S Dawe , DJ Kavanagh , RM Young (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 189, 137–143.
A Johns (2001). Psychiatric effects of cannabis. British Journal of Psychiatry 178, 116–122.
SH Jones , G Thornicroft , M Coffey , G Dunn (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). British Journal of Psychiatry 166, 654–659.
SR Kay , A Fiszbein , LA Opler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
MO Krebs , C Goldberger , A Dervaux (2005). Cannabis use and schizophrenia. American Journal of Psychiatry 162, 401–402.
TK Larsen , I Melle , B Auestad , S Friis , (2006). Substance abuse in first-episode non-affective psychosis. Schizophrenia Research 88, 55–62.
A Leung , P Chue (2000). Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica 101, 3–38.
DC Mathers , AH Ghodse (1992). Cannabis and psychotic illness. British Journal of Psychiatry 161, 648–653.
PK McGuire , P Jones , I Harvey , M Williams , (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 15, 277–281.
P Miller , SM Lawrie , A Hodges , R Clafferty , (2001). Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Social Psychiatry and Psychiatric Epidemiology 36, 338–342.
TH Moore , S Zammit , A Lingford-Hughes , TR Barnes , (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.
NIMH Genetics Initiative (1992). Family Interview for Genetic Studies (FIGS). Rockville, MD, National Institute of Mental Health, 1992.
JI Nurnberger Jr., MC Blehar , CA Kaufmann , C York-Cooler , (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry 51, 849–859.
M Pistis , S Perra , G Pillolla , M Melia , (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biological Psychiatry 56, 86–94.
HG Pope , AJ Gruber , JI Hudson , G Cohane , (2003). Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug and Alcohol Dependence 69, 303–310.
M Rais , W Cahn N Van Haren , H Schnack , (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 165, 490–496.
G Scheller-Gilkey , SM Thomas , BJ Woolwine , AH Miller (2002). Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophrenia Bulletin 28, 223–231.
E Schlicker , M Kathmann (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends in Pharmacological Sciences 22, 565–572.
M Schneider , M Koch (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760–1769.
M Schneider , M Koch (2005). Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30, 944–957.
JP Selten , N Veen , W Feller , JD Blom , (2001). Incidence of psychotic disorders in immigrant groups to The Netherlands. British Journal of Psychiatry 178, 367–372.
J Van Os , M Bak , M Hanssen , RV Bijl , R De Graaf , (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 156, 319–327.
JM Vanelle (1997). Refractory schizophrenia: historical and currently prevailing criteria and definitions. European Psychiatry 12 (Suppl. 5), 321s–326s.
ND Veen , JP Selten , I van der Tweel , WG Feller , (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry 161, 501–506.
H Verdoux , F Sorbara , C Gindre , JD Swendsen , (2002). Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophrenia Research 59, 77–84.
LN Voruganti , P Slomka , P Zabel , A Mattar , (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research 107, 173–177.
S Zammit , P Allebeck , S Andreasson , I Lundberg , (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 325, 1199–1201.